The risks and costs of multiple-generic substitution of topiramate


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
19528520

DOI
10.1212/WNL.0b013e3181aa5300

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Anticonvulsants /administration & dosage /adverse effects /economics; Chronic Disease /drug therapy; Cohort Studies; Comorbidity; Craniocerebral Trauma /epidemiology; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs /statistics & numerical data /trends; Drug Utilization /economics; Drugs, Generic /administration & dosage /adverse effects /economics; Epilepsy /drug therapy /epidemiology; Female; Fractures, Bone /epidemiology; Fructose /administration & dosage /adverse effects /analogs & derivatives /economics; Health Benefit Plans, Employee /economics; Health Care Costs /statistics & numerical data /trends; Hospitalization /statistics & numerical data; Humans; Insurance, Health, Reimbursement /economics; Male; Patient Acceptance of Health Care; Proportional Hazards Models; Quebec; Retrospective Studies; Risk Factors

AccessionNumber
22009102555

Date bibliographic record published
23/09/2009